Advertisement
Home »

High pCR Rates With Dual Neoadjuvant Immunotherapy in TIL-High TNBC

Nov 11, 2024

REFERENCES & ADDITIONAL READING

  1. Schmid P, et al. N Engl J Med. 2024;Sep 15, Online.
  2. Geurts VCM, et al. JAMA Oncol .2024;10:1077-1086.
  3. Tawbi HA, et al. N Engl J Med. 2022;386:24-34.
  4. Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). Abstract LBA11. ESMO Congress 2024, 13–17 September, Barcelona, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement